Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

Cancer

GSK Cuts Five-Year-Old Cancer Collaboration With Ideaya

GSK and Ideaya first linked up in 2020 to advance novel therapies for solid tumors. It is unclear why the pharma terminated the partnership.

December 8, 2025

2 min read

Tristan Manalac

Mental health, illness ,brain development ,medical treatment concept, messy lines of thinks in human head , vector illustration

Neuroscience

Biogen, Stoke Boost Epilepsy Drug’s Blockbuster Potential With Early Seizure Reduction Data

Analysts at Jefferies see blockbuster potential in zorevunersen in Dravet syndrome, with sales potentially reaching $1 billion to $4 billion.

December 8, 2025

2 min read

Tristan Manalac

In partnership with PII

Bridging Formulation and Device: Integrated Supply Chain Strategies for U.S. Pharma Manufacturing

The pharmaceutical supply chain and device development have become intricately linked. Harmonizing formulation development with drug delivery device design—and leveraging a single‐vendor ecosystem—can deliver significant time, cost, and regulatory advantages for US‑focused drug products, according to industry experts.

December 8, 2025

5 min read

Jennifer C. Smith-Parker

Balance, equilibrium and stability in a risky environment concepts. Spheres balancing on a seesaw. Abstract 3D render.

FDA

Rare Disease Leaders Call for Regulatory Consistency After Chaotic Year

As the FDA unveils a parade of initiatives aimed at accelerating drug development for rare diseases, experts appeal for a consistent approval process that will support and further catalyze momentum.

December 8, 2025

8 min read

Heather McKenzie

Sponsored

Accelerating Timelines and Reducing Cost in Early Clinical Drug Development With ICON’s Accelerated Pharmaceutical Solutions

Innovation drives speed in early phase drug development. ICON’s Accelerated Pharmaceutical Solutions integrate advanced formulation design, real-time dose flexibility, and cutting-edge CMC expertise to transform complexity into clarity. By uniting science, technology, and strategy, biotechs can move faster, smarter, and with confidence—turning obstacles into opportunities for breakthrough success.

December 8, 2025

5 min read

Arjen Akkerman

Mental Health Disorder Concept. Bipolar Disorder Person. Unstable Psycho. Layers of Paper Cut as Human Head presenting Different of Emotions. Happiness and Depression Emotion inside

Depression

5 Depression Trials That Failed in 2025

The R&D pipeline for depression therapies faced a demoralizing 2025 as five high-profile candidates, including KOR antagonists by Johnson & Johnson and Neumora Therapeutics, flunked late-stage clinical trials, underscoring the persistent challenges of CNS drug development.

December 8, 2025

6 min read

Ben Hargreaves

colorful low poly human brain vector illustration with wireframe and connected dots on purple illuminated background

Opinion

Patient-Centered Paradigms Can Boost Neuro Candidate Success Rates

Innovative outcome measures coupled with a focus on patient-centered clinical differentiation can help the biopharma industry make meaningful progress in the highly complex area of neuroscience.

December 8, 2025

5 min read

Bruce Leuchter

Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS).

Regulatory

In Change That Pushed Pazdur Out, FDA May Lower Clinical Trial Requirements

Commissioner Marty Makary said that the FDA will soon start requiring only one pivotal trial, instead of two, for companies seeking approval for new drugs.

December 5, 2025

2 min read

Dan Samorodnitsky